•   
  •   
  •   

Politics Experts fear political pressure on COVID-19 vaccine

15:05  02 august  2020
15:05  02 august  2020 Source:   thehill.com

UK signs up for Sanofi-GSK coronavirus vaccine

  UK signs up for Sanofi-GSK coronavirus vaccine Pharma giants Sanofi and GSK said Wednesday they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The deals involve 30 million doses of a vaccine being developed by US pharma giant Pfizer and Germany's BioNTech, and 60 million doses of another created by France's Valneva.The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract".

A retired major general who helped develop vaccines and ran the Walter Reed Army Institute of Research warns that it "could be terrible" if political pressure rushed a Covid - 19 vaccine .

Skip Ad. Associated Press . Fauci optimistic on COVID - 19 vaccine availability. Once a coronavirus vaccine is approved as safe and effective, Americans should have widespread access within a reasonable time, Dr. Anthony Fauci assured lawmakers Friday.

Public health experts are raising red flags that the Trump administration could exert political pressure on the Food and Drug Administration (FDA) to approve a COVID-19 vaccine before one is ready.

a person standing in front of a mirror posing for the camera: Experts fear political pressure on COVID-19 vaccine © Getty Experts fear political pressure on COVID-19 vaccine

President Trump, searching for a political win just over three months from the election, has latched onto the push for developing a vaccine in record time and promoted it in a number of recent appearances.

Moderna to charge $32 to $37 a dose for its COVID vaccine

  Moderna to charge $32 to $37 a dose for its COVID vaccine Moderna will charge between $32 and $37 a dose for its experimental coronavirus vaccine for some "low volume" customers, the company's CEO said WednesdayThe company will be using a tiered pricing system, and will charge less for higher volume orders. The company considers a small order to be "in the millions" of doses, CEO Stéphane Bancel said on a conference call to discuss the company's quarterly earnings.

A vaccine will become a powerful political tool, potentially freeing the citizens of the country that produces it from the shackles of life with coronavirus. Why We Might Not Need A Vaccine for COVID - 19 | This Morning - Продолжительность: 8:53 This Morning 957 409 просмотров.

While the world waits for a vaccine that could quash the pandemic, details and timelines keep shifting. Here's the latest on the race for a coronavirus vaccine

Trump spoke optimistically of the prospects for a vaccine during a visit to a biotech facility in North Carolina on Monday, despite experts cautioning one may not be widely available for another year.

The president made similar comments Thursday, touting progress without dwelling on the fact that more than 150,000 Americans have died due to the pandemic, a massive toll higher than any other country's.

"We are way ahead on vaccines, way ahead on therapeutics. And when we have it, we're all set up with our platforms to deliver them very, very quickly," Trump said during a White House press conference. "We're all set to deliver them as soon as we have them, and that's going to be very soon."

Novavax becomes fifth COVID-19 vaccine developer to release promising early results

  Novavax becomes fifth COVID-19 vaccine developer to release promising early results The candidate vaccine seems to have generated an immune reaction similar to those in people who have recovered from COVID-19, the data shows. True effectiveness cannot be determined until the vaccine candidate is tested in many more volunteers. Novavax has received $1.6 billion from the federal government to complete development of NVX‑CoV2373 and to scale up manufacturing. The government will own 100 million doses of the developmental vaccine.

Britain's Prime Minister Boris Johnson has postponed further easing of lockdown measures as COVID - 19 cases in England show signs they are increasing. The prevalence of coronavirus has moved from one in 1,800 to one in 1,500 in England, with a number of areas in northern England being

COVID - 19 , which has placed cities on the frontlines in the response to the crisis, has reminded us of the importance of the local dimension of development Excitement or fear refusing us to let rationality’s light in, we share. UNESCO experts views on the causes and consequences of COVID - 19 outbreak.

The president has sought to take credit for "Operation Warp Speed," the administration's multibillion-dollar effort to fund the development and distribution of potential vaccines for COVID-19 and have them available as soon as they are found to be safe and effective.

The administration has been buoyed by some early success reports from top vaccine candidates, and political officials have confidently predicted a shot will be available before the end of the year.

Anthony Fauci, the country's top infectious disease doctor, said Friday he is "cautiously optimistic" a vaccine will be ready by the end of 2020 and be widely distributed next year.

While there's almost no chance a vaccine would be ready for widespread distribution before Election Day in early November, some of the companies with vaccine candidates entering the phase three clinical trial stages now might start to show initial results by then.

Novavax becomes fifth COVID-19 vaccine developer to release promising early results

  Novavax becomes fifth COVID-19 vaccine developer to release promising early results The candidate vaccine seems to have generated an immune reaction similar to those in people who have recovered from COVID-19, the data shows. True effectiveness cannot be determined until the vaccine candidate is tested in many more volunteers. Novavax has received $1.6 billion from the federal government to complete development of NVX‑CoV2373 and to scale up manufacturing. The government will own 100 million doses of the developmental vaccine.

COVID - 19 and the Need for Action on Mental Health. Before COVID - 19 emerged, statistics on mental health conditions (including neurological and sub-stance use disorders Demand for face-to-face mental health services has significantly decreased because of fear of infection, particularly among

The concern about COVID - 19 is that, unlike influenza, there is no vaccine and no specific treatment for the disease. There are currently no vaccines against human coronaviruses, including the virus that causes COVID - 19 . This is why it is very important to prevent infection and to take measures to contain

Researchers and experts said they are worried Trump could seize on those early results to pressure public health agencies into approving a vaccine before it is ready.

"You saw the issue of politicization around hydroxychloroquine and the pressure that was put on FDA then. There's a legitimate concern that does not happen again," said Jesse Goodman, a Georgetown University professor who was previously FDA's chief scientific officer.

Many outside observers felt the FDA bowed to political pressure earlier this year when the agency issued an emergency authorization for hydroxychloroquine, an anti-malaria drug that Trump, his allies and members of his administration have continued to tout as a miracle cure for COVID-19 despite evidence.

Rick Bright, an agency whistleblower, made similar accusations and said he lost his job for objecting to the drug's widespread promotion.

The FDA later revoked the authorization.

In another instance, the White House reportedly pressured the Centers for Disease Control and Prevention (CDC) to change its guidance on reopening schools in order to emphasize the importance of kids going to school while downplaying any potential risks.

Most voters say they'd rather wait for an effective coronavirus vaccine

  Most voters say they'd rather wait for an effective coronavirus vaccine The findings raise fresh questions about the success of U.S vaccination efforts if an effective vaccine emerges.Just 22 percent of respondents said the government should make a vaccine available as soon as possible, even if it had not been fully tested. Republicans (26 percent) were slightly more likely than Democrats (21 percent) to favor getting a vaccine out as quickly as possible.

(If the Covid - 19 study comes to fruition, experts say it would likely be administered by nose drop.) But if it's high reward, it's also high risk: Although Covid - 19 is a much more deadly disease for the elderly and the compromised than healthy young adults, it is an unpredictable pathogen that has put

Know how coronavirus ( COVID - 19 ) spreads and take steps to protect yourself and others. Avoid close contact, clean your hands often, cover coughs and sneezes, stay home if you’re sick, and know how to clean and disinfect. There is currently no vaccine to prevent coronavirus disease 2019 ( COVID - 19 ).

Goodman said even if there is no political pressure on a COVID-19 vaccine, there's still "a legitimate problem in public perception" because of the administration's past actions in other areas of the crisis.

An ABC News/Washington Post poll released in July found that more than half the country distrusts Trump while six in 10 Americans disapprove of his handling of the virus outbreak overall.

A separate poll released this week found that 64 percent favor fully testing any potential vaccine, even if doing so delays its release and allows the disease to potentially spread further.

Health experts warn about the danger of a widespread portion of the population rejecting a vaccine once one is available.

Top administration officials are working hard to reassure the public that they will not be cutting any corners.

"Data and science. Those are what's going to guide us," FDA Commissioner Stephen Hahn said during a recent interview with the Journal of the American Medical Association. "We cannot have a situation where people lose trust in the FDA and the clinical trials process."

Hahn said the FDA's decisions have worldwide implications, beyond just a COVID-19 vaccine.

"America and the world's public trust in FDA is really important. It's worth a lot because people depend upon us every day in their lives, and we just cannot do anything that would break that trust, and that's a solemn promise," Hahn said.

'Vaccine nationalism': Is it every country for itself?

  'Vaccine nationalism': Is it every country for itself? 'Vaccine nationalism': Is it every country for itself?LONDON/CHICAGO (Reuters) - It's dog eat dog in the world of COVID-19 vaccines.

FDA guidance requires any vaccine approved to be at least 50 percent more effective than a placebo in preventing the disease, among other criteria.

Drug executives have said they do not believe the FDA would lower its standards for approval.

Still, a potential workaround exists: the agency could issue an emergency use authorization, which requires less rigorous data than a full approval, as soon as officials are convinced a vaccine is safe and effective.

Goodman said all agencies involved in the decisionmaking need to be as transparent as possible.

"I don't think emergency use authorization should be trivialized on very limited data, and I think the data need to be spelled out to people," Goodman said.

Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security, said he thinks there are enough outside players involved that the Trump administration would be hard-pressed to push a vaccine based on limited evidence.

"My confidence is not in the White House managing this, but in the pharmaceutical companies that have delivered hundreds and millions of doses of vaccines for many different problems over time," Adjala said.

Still, he said public skepticism will be hard to overcome.

"If politicians get involved in vaccine decisionmaking, that is going to be tainted, because everything that politicians have touched so far in this pandemic has been compromised by their involvement in it," Adjala said.

"This is not a place that politicians really need to insert themselves. This is a medical decision between doctors and patients."

Russian Health Minister Says Mass COVID-19 Vaccination is Being Planned for October

  Russian Health Minister Says Mass COVID-19 Vaccination is Being Planned for October Mikhail Murashko said clinical trials had been completed as Russia pushes to become the first country to develop a vaccine.Mikhail Murashko has said that clinical trials had been completed at the state research facility in Moscow, the Gamaleya Institute, and that the vaccine was now being registered.


Video: FDA commissioner: ‘We will not cut corners’ on a coronavirus vaccine (TODAY)

Trump hits road to tout progress toward vaccine .
MORRISVILLE, N.C. - President Trump and Vice President Pence hit the road on Monday to highlight progress on the development of a vaccine for COVID-19, seeking to project optimism about the administration's response to a pandemic that has killed more than 145,000 people in the U.S.Trump visited a biotech facility here to boast of the rapid progress on finding a vaccine to combat the pandemic, claiming his administration's work through itsTrump visited a biotech facility here to boast of the rapid progress on finding a vaccine to combat the pandemic, claiming his administration's work through its vaccine development effort, "Operation Warp Speed," had reduced the wait time by "years.

—   Share news in the SOC. Networks
usr: 1
This is interesting!